NCT06427811

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

CompletedPHASE4INTERVENTIONAL

Trial Details

Start: 2024-11-28Est. Completion: 2026-03-18

Enrollment target: 85 participants

Locations

Novartis Investigative Site, Ahmedabad, Gujarat, India
Novartis Investigative Site, Ahmedabad, Gujarat, India
Novartis Investigative Site, Bengaluru, Karnataka, India
Novartis Investigative Site, Trivandrum, Kerala, India
Novartis Investigative Site, Pune, Maharashtra, India
Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site, Hyderabad, Telangana, India
Novartis Investigative Site, Kolkata, West Bengal, India
Novartis Investigative Site, Cuttack, India
Novartis Investigative Site, Guwahati, India

Other microbiome trials you might be interested in

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesPhase 1Recruiting

Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…

Bethesda, United StatesEst. completion Apr 30, 2029

View Trial →

Asciminib With or Without Sildenafil for Brain Tumors

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.